Header

UZH-Logo

Maintenance Infos

Impfung von Katzen gegen die Infektion mit dem felinen Leukämievirus (FeLV) : erster rekombinanter Impfstoff und Einfluss einer vorbestehenden Infektion mit dem felinen Immunschwächevirus (FIV)


Hofmann-Lehmann, Regina; Aubert, Andre; Wolfensberger, C; Cronier, J; Lutz, Hans (1994). Impfung von Katzen gegen die Infektion mit dem felinen Leukämievirus (FeLV) : erster rekombinanter Impfstoff und Einfluss einer vorbestehenden Infektion mit dem felinen Immunschwächevirus (FIV). Schweizer Archiv für Tierheilkunde, 136(10):340-351.

Abstract

A new recombinant FeLV vaccine was evaluated in 30 specified pathogen-free cats 10 months of age cats. The vaccine consisted of the non-glycosylated FeLV envelope protein p45, aluminium hydroxide and a saponin adjuvant. The cats (n = 18) were vaccinated twice intramuscularly, 3 weeks apart. All animals were challenged intraperitoneally with FeLV subgroup A, 18 weeks later. While 94% of the vaccinated cats showed no viraemia or were only transiently viraemic, 80% of the non-vaccinated animals became persistently viraemic within 2 to 3 weeks. In our hands the preventable fraction of the vaccine was 93%. In order to determine the effect of a pre-existing infection with feline immunodeficiency virus on the efficacy of vaccination, 50% of the cats were previously infected with FIV. The infected cats were protected to the same degree as the non-infected animals. With prolonged duration of FIV infection the probability increases, that the immune system of the cat will fail and clinical signs will appear. In order to observe a state of possible immunodeficiency, an accurate clinical examination of every cat prior to vaccination seems of major importance.

Abstract

A new recombinant FeLV vaccine was evaluated in 30 specified pathogen-free cats 10 months of age cats. The vaccine consisted of the non-glycosylated FeLV envelope protein p45, aluminium hydroxide and a saponin adjuvant. The cats (n = 18) were vaccinated twice intramuscularly, 3 weeks apart. All animals were challenged intraperitoneally with FeLV subgroup A, 18 weeks later. While 94% of the vaccinated cats showed no viraemia or were only transiently viraemic, 80% of the non-vaccinated animals became persistently viraemic within 2 to 3 weeks. In our hands the preventable fraction of the vaccine was 93%. In order to determine the effect of a pre-existing infection with feline immunodeficiency virus on the efficacy of vaccination, 50% of the cats were previously infected with FIV. The infected cats were protected to the same degree as the non-infected animals. With prolonged duration of FIV infection the probability increases, that the immune system of the cat will fail and clinical signs will appear. In order to observe a state of possible immunodeficiency, an accurate clinical examination of every cat prior to vaccination seems of major importance.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

0 downloads since deposited on 23 Dec 2016
0 downloads since 12 months

Additional indexing

Other titles:Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)
Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Farm Animals
Dewey Decimal Classification:570 Life sciences; biology
630 Agriculture
Language:German
Date:1994
Deposited On:23 Dec 2016 09:11
Last Modified:20 Feb 2018 12:03
Publisher:Gesellschaft Schweizer Tierärztinnen und Tierärzte
ISSN:0036-7281
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Related URLs:http://doi.org/10.5169/seals-592583 (Library Catalogue)
PubMed ID:7801087

Download